MediGene Concludes Agreement with Juste for the Commercialization of Veregen in Spain and Portugal
MediGene to receive milestone payments totalling up to 2,550,000 euro and royalties on future sales
MediGene AG has entered into a marketing partnership with the Spanish company Juste S.A.Q.F. for the commercialization of Veregen® ointment (formerly Polyphenon E®) in Spain and Portugal. Juste will promote and distribute the drug for the treatment of genital warts. Depending on specified milestones and sales targets achieved, MediGene is entitled to successive payments totalling up to 2,550,000 euro. MediGene will supply Juste with the finished product, and will receive royalties on the sales revenue for Veregen®.
Veregen® is currently undergoing a decentralized procedure in Germany, Austria, and Spain, and conclusion of this process is expected soon. Thereafter, MediGene is planning to apply for approval in further European countries. MediGene intends to conclude additional marketing agreements for countries in and outside Europe.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.